Compare AVX & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVX | GRML |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 29.2M |
| IPO Year | 2020 | 2022 |
| Metric | AVX | GRML |
|---|---|---|
| Price | $4.53 | $4.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 232.4K | ★ 3.0M |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.55 | 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,340,811.00 | N/A |
| Revenue This Year | $18,042.77 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3348.10 | N/A |
| 52 Week Low | $0.35 | $0.16 |
| 52 Week High | $7.38 | $18.21 |
| Indicator | AVX | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 40.63 |
| Support Level | $3.02 | $0.28 |
| Resistance Level | $6.25 | $7.53 |
| Average True Range (ATR) | 0.65 | 0.61 |
| MACD | -0.05 | -0.24 |
| Stochastic Oscillator | 39.83 | 4.09 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.